Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
GLOBETECH PUBLISHING LLC
Ampronix

Early PET-Negative Stage I/II Hodgkin Lymphoma Patients Show Increased Risk of Early Relapse when Radiotherapy Is Not Used

By Medimaging International staff writers
Posted on 23 Apr 2014
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Analysis of a new study indicates an increased risk of early relapse when excluding radiotherapy in early positron emission tomography (PET) scan-negative patients with stage I/II Hodgkin’s lymphoma.

The interim analysis of the intergroup EORTC-LYSA-FIL 20051 H10 trial was published online March 17, 2014, in the Journal of Clinical Oncology. Early outcome, however, was excellent in both arms, and the final analysis should reveal whether these preliminary findings are upheld over time.

Dr. J.M.M. Raemaekers, from the Radboud University Medical Center (Nijmegen, The Netherlands), and central coordinator of the study stated, “The standard treatment for patients with clinical stage I/II Hodgkin’s lymphoma is ABVD [adriamycin, bleomycin, vinblastin and dacarbazin] chemotherapy followed by radiotherapy. Striking the right balance between initial cure through combined modality treatment and accepting a higher risk of late complications, and a higher recurrence rate after omitting radiotherapy in subsets of patients who will subsequently need intensive salvage treatment, is a matter of unsettled debate.”

The main objective of the H10 trial was to evaluate whether involved-node radiotherapy could be omitted without loss of efficacy in terms of progression-free survival in patients with stage I/II Hodgkin’s lymphoma who had a negative early PET scan after two cycles of ABVD chemotherapy. This interim trial analysis included a total of 1,137 patients with untreated clinical stage I/II Hodgkin’s lymphoma. Of these, 444 patients had favorable and 693 unfavorable prognoses. Patients in each prognostic group were randomized between standard and experimental treatment and first received two cycles of ABVD chemotherapy. Patients in the experimental arm who attained a negative early PET scan after the two cycles of ABVD chemotherapy were spared involved-node radiotherapy.

One progression occurred in the standard arm and nine progressions occurred in the research arm, for patients with a favorable prognosis and a negative early PET scan. For patients with unfavorable prognosis and a negative early PET scan, seven events occurred in the standard arm and 16 events occurred in the research arm. Even though there were few events and the median follow-up time short, the Independent Data Monitoring Committee concluded it was unlikely that the final results would show noninferiority for the experimental treatment. They, therefore, advised that randomization should be stopped for early PET-negative patients.
The study was closed for recruitment in June 2011 with a total of 1952 patients. The intergroup EORTC 20051 H10 trial is coordinated by the EORTC Lymphoma Group in collaboration with the LYmphoma Study Association (LYSA) and the Fondazione Italiana Linfomi (FIL). It is being conducted in 159 sites in eight countries: Belgium, Croatia, Denmark, France, Italy, Slovakia, Switzerland, and The Netherlands.

Related Links:

Radboud University Medical Center



Channels

Radiography

view channel

Results of a Study into the Use of Low-Tube-Voltage for CT Colonography Published

Researchers from the Department of Diagnostic Radiology, at the Kumamoto University (Kumamoto, Japan) investigating the effect of a low-tube voltage technique and iterative reconstruction on the image quality and radiation dose of Computed Tomography Colonography (CTC), have been published in the April 11, 2015, online... Read more

MRI

view channel
Image: The ViewRay MRIdian System (Photo courtesy of ViewRay).

Unique MRI-Guided Radiation Therapy System Showcased at ESTRO 2015

ViewRay (Cleveland OH, USA) has demonstrated their advanced radiation therapy technology for the treatment of cancer at the April, 2015, European Society for Therapeutic Radiology and Oncology (ESTRO)... Read more

Ultrasound

view channel

Ultrasound Device Reduces the Number of Tests Required for Inpatients and Outpatients

The results of a study carried out by the European Association for the Study of the Liver (EASL; Geneva, Switzerland) into the use of a Pocket-sized Ultrasound Device (PUD) together with a physical examination, have been presented at the 2015 International Liver Congress, in Vienna (Austria). The study evaluated the... Read more

General/Advanced Imaging

view channel

Global Healthcare Study of Coronary Artery Disease Reaches Significant Milestone

A major milestone has been reached in the Lipid-Rich Plaque (LRP) study, a prospective, multicenter clinical trial with the potential to reveal breakthrough correlations between Lipid-Rich Plaques and occurrence of heart attacks. The LPR study has now enrolled 1,000 patients, and aims to identify a correlation between... Read more

Imaging IT

view channel
Image: Clinical Collaboration Platform (Photo courtesy of Carestream Healthcare).

New, Advanced Medical Imaging and Healthcare IT Products Showcased in HIT Expo in Paris

A medical imaging systems and Information Technology (IT) solutions provider has demonstrated its advanced imaging IT platform and product updates at Health-IT (HIT) Expo 2015 on May 19–21, in Paris (France).... Read more

Industry News

view channel

Advanced Medical Imaging Startup Company Receives Venture Funding

Zebra Medical Vision (Kibbutz Shfayim, Israel) has received an USD 8 million investment from Khosla Ventures (Menlo Park, CA, USA) to double its team, set up headquarters in the US and increase its scope of work to integrate data from additional Health Maintenance Organizations (HMO). Zebra Medical has already partnered... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.